Eczema can be managed with certain self-care ... or mycophenolate mofetil Biologic agents, such as dupilumab (Dupixent) or lebrikizumab-lbkz (Ebglyss), are reserved for people who have tried ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
If none of these treatments work for you, the FDA has approved the drug for moderate to severe eczema called dupilumab (Dupixent). Your doctor will have to prescribe it. You take it in the form of ...
Lilly hopes that "patients see themselves reflected in the commercial," says Ashley Diaz-Granados, SVP of U.S. immunology ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Dupixent may become the first targeted treatment ... to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled ...
Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...
The sBLA is supported by data from a pivotal trial evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP. The primary endpoint was met, with five times more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results